Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20050187611 A1
Publication typeApplication
Application numberUS 11/116,256
Publication dateAug 25, 2005
Filing dateApr 27, 2005
Priority dateApr 19, 1995
Also published asDE69839869D1, EP0923953A2, EP0923953A3, EP0923953B1, EP1980278A2, EP1980278A3, US6099562, US6284305, US6620194, US20020004101, US20040049265, US20050208200
Publication number11116256, 116256, US 2005/0187611 A1, US 2005/187611 A1, US 20050187611 A1, US 20050187611A1, US 2005187611 A1, US 2005187611A1, US-A1-20050187611, US-A1-2005187611, US2005/0187611A1, US2005/187611A1, US20050187611 A1, US20050187611A1, US2005187611 A1, US2005187611A1
InventorsNi Ding, Michael Helmus
Original AssigneeBoston Scientific Scimed, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Drug coating with topcoat
US 20050187611 A1
Abstract
A coating and method for a coating an implantable device or prostheses are disclosed. The coating includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed herein. The coating further includes a topcoat which covers less than the entire surface of the undercoat and wherein the topcoat comprises a polymeric material substantially free of pores and porosigens. The polymeric material of the topcoat can be a biostable, biocompatible material which provides long term non-thrombogenicity to the device portion during and after release of the biologically active material.
Images(10)
Previous page
Next page
Claims(20)
1-50. (canceled)
51. A medical device comprising:
a metallic intravascular stent comprising an open lattice sidewall structure and designed for permanent implantation into a blood vessel of a patient;
a first quantity of a first polymer composition applied to at least a portion of said stent and conforming to said open lattice sidewall structure so as to preserve the open lattice sidewall structure of said stent, wherein said first polymer composition comprises a first biostable polymer and a biologically active material; and
a second quantity of a second polymer composition applied to at least a portion of said first quantity and conforming to said stent so as to preserve the open lattice sidewall structure of said stent, wherein said second polymer composition comprises a second biostable polymer that is different from said first biostable polymer, and wherein said second polymer composition is non-thrombogenic and substantially free of the biologically active material or other elutable material,
wherein when in use, the biologically active material is released from the stent to the blood vessel at a first rate that is different from a second rate, wherein the second rate is the rate of release of the same biologically active material from the stent had the second quantity of the second polymer composition not been applied to the first quantity of the first polymer composition.
52. The medical device of claim 51, wherein the metallic intravascular stent is a stainless steel intravascular stent.
53. The medical device of claim 51, wherein the first quantity of first polymer composition is different from the second quantity of second polymer composition.
54. The medical device of claim 51, wherein the first biostable polymer comprises a hydrophobic elastomeric material, an ethylene vinyl acetate copolymer material, or a mixture thereof.
55. The medical device of claim 51, wherein the biologically active material is an antithrobotic agent, anticoagulant, antibiotic, antiplatelet agent, thrombolytic agent, antiproliferative agent, steroidal antiinflammatory agent, nonsteroidal antiinflammatory agent, agent that inhibits hyperplasia, smooth muscle cell inhibitor, growth factor, growth factor inhibitor, cell adhesion inhibitor, cell adhesion promoter, drug that enhances the formation of healthy neointimal tissue, or a mixture thereof.
56. The medical device of claim 51, wherein the biologically active material is an antibiotic.
57. The medical device of claim 51, wherein the biologically active material inhibits smooth muscle cell.
58. The medical device of claim 51, wherein the biologically active material inhibits restenosis.
59. The medical device of claim 51, wherein the second biostable polymer remains non-thrombogenic during and after release of the biologically active material.
60. The medical device of claim 51, wherein the stent releases the biologically active material over a period of time.
61. A method of treating restenosis comprising implanting the medical device of claim 51 into the blood vessel of the patient.
62. A medical device comprising:
a metallic intravascular stent comprising an open lattice sidewall structure and designed for permanent implantation into a blood vessel of a patient;
a first quantity of a first polymer composition applied to at least a portion of said stent and conforming to said open lattice sidewall structure so as to preserve the open lattice sidewall structure of said stent, wherein said first polymer composition comprises an ethylene vinyl acetate copolymer material and an antibiotic; and
a second quantity of a second polymer composition applied to at least a portion of said first quantity and conforming to said stent so as to preserve the open lattice sidewall structure of said stent, wherein said second polymer composition comprises a second biostable polymer that is different from the ethylene vinyl acetate copolymer material of said first polymer composition, and wherein said second polymer composition is non-thrombogenic and substantially free of the antibiotic of the first polymer composition or other elutable material,
wherein when in use, the antibiotic is released from the stent to the blood vessel at a first rate that is different from a second rate, wherein the second rate is the rate of release of the same antibiotic from the stent had the second quantity of the second polymer composition not been applied to the first quantity of the first polymer composition.
63. The medical device of claim 62, wherein the metallic intravascular stent is a stainless steel intravascular stent.
64. The medical device of claim 62, wherein the first quantity of first polymer composition is different from the second quantity of second polymer composition.
65. The medical device of claim 62, wherein the antibiotic inhibits smooth muscle cell.
66. The medical device of claim 62, wherein the antibiotic inhibits restenosis.
67. The medical device of claim 62, wherein the second biostable polymer remains non-thrombogenic during and after release of the antibiotic.
68. The medical device of claim 62, wherein the stent releases the antibiotic over a period of time.
69. A method of treating restenosis comprising implanting the medical device of claim 62 into the blood vessel of the patient.
Description
    CROSS-REFERENCE TO RELATED APPLICATIONS
  • [0001]
    The present application is a Continuation-In-Part of co-pending application Ser. No. 08/633,518, filed Jun. 13, 1996.
  • BACKGROUND OF THE INVENTION
  • [0002]
    1. Field of the Invention
  • [0003]
    The present invention relates generally to providing biostable elastomeric coatings on the surfaces of implants which incorporate biologically active species having controlled release characteristics in the coating and relates particularly to providing a non-thrombogenic surface during and after timed release of the biologically active species. The invention is particularly described in terms of coatings on therapeutic expandable stent prostheses for implantation in body lumens, e.g., vascular implantation.
  • [0004]
    2. Related Art
  • [0005]
    In surgical or other related invasive procedures, the insertion and expansion of stent devices in blood vessels, urinary tracts or other locations difficult to otherwise access for the purpose of preventing restenosis, providing vessel or lumen wall support or reinforcement and for other therapeutic or restorative functions has become a common form of long-term treatment. Typically, such prostheses are applied to a location of interest utilizing a vascular catheter, or similar transluminal device, to carry the stent to the location of interest where it is thereafter released to expand or be expanded in situ. These devices are generally designed as permanent implants which may become incorporated in the vascular or other tissue which they contact at implantation.
  • [0006]
    One type of self-expanding stent has a flexible tubular body formed of several individual flexible thread elements each of which extends in a helix configuration with the centerline of the body serving as a common axis. The elements are wound in the same direction but are displaced axially relative to each other and meet, under crossing a like number of elements also so axially displaced, but having the opposite direction of winding. This configuration provides a resilient braided tubular structure which assumes stable dimensions upon relaxation. Axial tension produces elongation and corresponding diameter contraction that allows the stent to be mounted on a catheter device and conveyed through the vascular system as a narrow elongated device. Once tension is relaxed in situ, the device at least substantially reverts to its original shape. Prostheses of the class including a braided flexible tubular body are illustrated and described in U.S. Pat. Nos. 4,655,771 and 4,954,126 to Wallsten and U.S. Pat. No. 5,061,275 to Wallsten et al.
  • [0007]
    Implanted stents have been used to carry medicinal agents, such as thrombolytic agents. U.S. Pat. No. 5,163,952 to Froix discloses a thermalmemoried expanding plastic stent device formulated to carry a medicinal agent in the material of the stent itself. Pinchuk, in U.S. Pat. No. 5,092,877, discloses a stent of a polymeric material which may have a coating associated with the delivery of drugs. Other patents which are directed to devices of the class utilizing bio-degradable or bio-sorbable polymers include Tang et al., U.S. Pat. No. 4,916,193, and MacGregor, U.S. Pat. No. 4,994,071.
  • [0008]
    A patent to Sahatjian, U.S. Pat. No. 5,304,121, discloses a coating applied to a stent consisting of a hydrogel polymer and a preselected drug such as a cell growth inhibitors or heparin. A further method of making a coated intravascular stent carrying a therapeutic material is described in Berg et al., U.S. Pat. No. 5,464,650, issued on Nov. 7, 1995 and corresponding to European Patent Application No. 0 623 354 A1 published 9 Nov. 1994. In that disclosure, a polymer coating material is dissolved in a solvent and the therapeutic material dispersed in the solvent; the solvent evaporated after application.
  • [0009]
    An article by Michael N. Helmus (a co-inventor of the present invention) entitled “Medical Device Design—A Systems Approach: Central Venous Catheters”, 22nd International Society for the Advancement of Material and Process Engineering Technical Conference (1990) relates to polymer/drug/membrane systems for releasing heparin. Those polymer/drug/membrane systems require two distinct types of layers to function.
  • [0010]
    It has been recognized that contacting blood with the surface of a foreign body in vivo has a tendency to induce thrombogenic responses and that as the surface area of a foreign device in contact with host blood increases, the tendency for coagulation and clot forming at these surfaces also increases. This has led to the use of immobilized systemic anti-coagulant or thrombolytic agents such as heparin on blood contacting surfaces such as oxygen uptake devices to reduce this phenomenon. Such an approach is described by Winters, et al., in U.S. Pat. Nos. 5,182,317; 5,262,451 and 5,338,770 in which the amine functional groups of the active material are covalently bonded using polyethylene oxide (PEO) on a siloxane surface.
  • [0011]
    Another approach is described in U.S. Pat. No. 4,613,665 to Larm in which heparin is chemically covalently bound to plastic surface materials containing primary amino groups to impart a non-thrombogenic surface to the material. Other approaches for bonding heparin are described in Barbucci, et al., “Coating of commercially available materials with a new heparinizable material”, Journal of Biomedical Materials Research, Vol. 25, pp. 1259-1274 (1991); Hubbell, J. A., “Pharmacologic Modification of Materials”, Cardiovascular Pathology, Vol. 2, No. 3 (Suppl.), 121S-127S (1993); Gravlee, G. P., “Heparin-Coated Cardiopulmonary Bypass Circuits”, Journal of Cardiothoracic and Vascular Anesthesia, Vol. 8, No. 2, pp. 213-222 (1994).
  • [0012]
    Moreover, drug elution rates for a coating containing a hydrophilic or a lipophobic drug is usually very fast initially when the coated device contacts body fluid or blood. One of the methods to reduce the so called “burst effect” is to add a membrane containing porosigen over the coating layer containing the biologically active material. See e.g., U.S. Pat. No. 5,605,696 to Eury et al. and U.S. Pat. No. 5,447,724 to Helmus et al. When the porosigen elutes, a porous membrane is formed and the drug in the undercoat will release. Even though the method might be quite successful to control the drug release, it increases the coating thickness, reduces the effective drug loading and introduces undesirable additional foreign materials into the patient. Hence, there is a need for a coating which reduces the burst effect but is not too thick and does not require the release of porosigens into the body.
  • [0013]
    With regard to stents, polymeric stents, although effective, may have mechanical properties that are inferior to those of metal stents of like thickness and weave. Metallic vascular stents braided of even relatively fine metal can provide a large amount of strength to resist inwardly directed circumferential pressure. A polymer material of comparable strength requires a much thicker-walled structure or heavier, denser filament weave, which in turn, reduces the cross-sectional area available for flow through the stent and/or reduces the relative amount of open space in the weave. Also, it is usually more difficult to load and deliver polymeric stents using catheter delivery systems.
  • [0014]
    While certain types of stents such as braided metal stents may be preferred for some applications, the coating and coating modification process of the present invention is not so limited and can be used on a wide variety of prosthetic devices. Thus, in the case of stents, the present invention also applies, for example, to the class of stents that are not self-expanding, including those which can be expanded, for instance, with a balloon; as well as polymeric stents of all kinds. Other medical devices that can benefit from the present invention include blood exchanging devices, vascular access ports, central venus catheters, cardiovascular catheters, extracorpeal circuits, vascular grafts, pumps, heart valves, and cardiovascular sutures, to name a few. Regardless of detailed embodiments, applicability of the invention should not be considered limited with respect to implant design, implant location or materials of construction. Further, the present invention may be used with other types of implantable prostheses.
  • [0015]
    Accordingly, it is a primary object of the present invention to provide a coating and process for coating a stent to be used as a deployed stent prostheses, the coating being capable of effective controlled long-term delivery of biologically active materials.
  • [0016]
    Another object of the invention is to provide a coating and process for coating a stent prostheses using a biostable hydrophobic elastomer in which biologically active species are incorporated within a coating.
  • [0017]
    Still another object of the present invention is to provide a multi-layer coating and process for the delivery of biologically active species in which the percentage of active material can vary from layer to layer.
  • [0018]
    Yet another object of the present invention is to provide a multi-layer coating and process for the delivery of biologically active species from a coating with a non-thrombogenic surface.
  • [0019]
    Another object of the invention is to provide a coating for the delivery of biologically active species having a top layer or topcoat which reduces the initial release of the species, in which the topcoat is substantially free of pores or porosigens and covers less than the entire surface of the undercoat. The topcoat can cover less than the entire surface of the undercoat before and/or while the device is implanted.
  • [0020]
    A further object of the invention is to provide a multilayer coating for the delivery of biologically active species such as heparin having a fluorosilicone top layer.
  • [0021]
    A still further object of the invention is to provide a multi-layer coating for the delivery of biologically active species such as heparin having a surface containing immobilized polyethylene glycol (PEG).
  • [0022]
    Other objects and advantages of the present invention will become apparent to those skilled in the art upon familiarization with the specification and appended claims.
  • SUMMARY OF THE INVENTION
  • [0023]
    The present invention provides a relatively thin layered coating of biostable elastomeric material containing an amount of biologically active material dispersed therein in combination with a non-thrombogenic surface that is useful for coating the surfaces of prostheses such as deployable stents.
  • [0024]
    The preferred stent to be coated is a self-expanding, open-ended tubular stent prostheses. Although other materials, including polymer materials, can be used, in the preferred embodiment, the tubular body is formed of a self expanding open braid of fine single or polyfilament metal wire which flexes without collapsing, readily axially deforms to an elongate shape for transluminal insertion via a vascular catheter and resiliently expands toward predetermined stable dimensions upon removal in situ.
  • [0025]
    In the process, the initial coating is preferably applied as a mixture, solution or suspension of polymeric material and finely divided biologically active species dispersed in an organic vehicle or a solution or partial solution of such species in a solvent or vehicle for the polymer and/or biologically active species. For the purpose of this application, the term “finally divided” means any type or size of included material from dissolved molecules through suspensions colloids and particulate mixtures. The biologically active material is dispersed in a carrier material which may be the polymer, a solvent, or both. The coating is preferably applied as a plurality of relatively thin layers sequentially applied in relatively rapid sequence and is preferably applied with the stent in a radially expanded state.
  • [0026]
    In many applications the layered coating is referred to or characterized as including an undercoat and topcoat. The coating thickness ratio of the topcoat to undercoat may vary with the desired effect and/or the elution system. Typically these are of different formulations with most or all of the biologically active material being contained in the undercoat and a non-thrombogenic or biocompatible non-porous surface found in the topcoat.
  • [0027]
    It is desirable that the topcoat be substantially free of connected pores or porosigens (materials which can elute during implantation and form pores). The addition of a porous membrane as a top coat will increase the coating thickness and reduce the overall drug loading. Also, the release of porosigens into the body can be undesirable since it introduces additional foreign materials into the body, which can cause the patient to have adverse reactions.
  • [0028]
    Since in some embodiments the topcoat should be substantially free of pores, the topcoat should cover less than the entire surface of the undercoat. Preferably, the topcoat should cover only about 10% to about 95% of the surface of the undercoat.
  • [0029]
    By partially covering the surface during manufacture or inducing “breaks” in the topcoat during mounting/implanting of the coated device, the biologically active material or drug of the undercoat is permitted to be released from the undercoat through those parts of the undercoat which are not covered by the topcoat.
  • [0030]
    This mechanism is illustrated by FIG. 9, which shows a surface of a prosthesis 101 covered by a coating 102 comprising an undercoat 103 and a topcoat 104. The topcoat 104, which only partially covers the undercoat 103, leaves certain areas 106 of the undercoat, including drug particles 105, exposed to body fluids at the implantation site. It is through these “uncovered” areas 106 of the undercoat that the drug particles 105 of the undercoat 103 are allowed to be released into the implantation site.
  • [0031]
    Additionally, it is preferred that the topcoats have an average thickness equivalent to the average particle size of the drug in the undercoat. Preferably the average thickness is about 1 to 7 microns and more preferable that the topcoat average thickness be about 1 to 5 microns. Also, the polymer of the topcoat may be the same as or different from the polymer of the undercoat.
  • [0032]
    The coating may be applied by dipping or spraying using evaporative solvent materials of relatively high vapor pressure to produce the desired viscosity and quickly establish coating layer thicknesses. The preferred process is predicated on reciprocally spray coating a rotating radially expanded stent employing an air brush device. The coating process enables the material to adherently conform to and cover the entire surface of the filaments of the open structure of the stent but in a manner such that the open lattice nature of the structure of the braid or other pattern is preserved in the coated device.
  • [0033]
    The coating is exposed to room temperature ventilation for a predetermined time (possibly one hour or more) for solvent vehicle evaporation. In the case of certain undercoat materials, thereafter the polymer material is cured at room temperature or elevated temperatures. Curing is defined as the process of converting the elastomeric or polymeric material into the finished or useful state by the application of heat and/or chemical agents which induce physico-chemical changes. Where, for example, polyurethane thermoplastic elastomers are used as an undercoat material, solvent evaporation can occur at room temperature rendering the undercoat useful for controlled drug release without further curing.
  • [0034]
    The applicable ventilation time and temperature for cure are determined by the particular polymer involved and particular drugs used. For example, silicone or polysiloxane materials (such as polydimethylsiloxane) have been used successfully. Urethane prepolymers can also be utilized. Unlike the polyurethane thermoplastic elastomers, some of these materials are applied as prepolymers in the coating composition and must thereafter be heat cured. The preferred silicone species have a relatively low cure temperatures and are known as a room temperature vulcanizable (RTV) materials. Some polydimethylsiloxane materials can be cured, for example, by exposure to air at about 90° C. for a period of time such as 16 hours. A curing step may be implemented both after application of the undercoat or a certain number of lower layers and the top layers or a single curing step used after coating is completed.
  • [0035]
    The coated stents may thereafter be subjected to a postcure process which includes an inert gas plasma treatment, and sterilization which may include gamma radiation, ETO treatment, electron beam or steam treatment.
  • [0036]
    In the plasma treatment, unconstrained coated stents are placed in a reactor chamber and the system is purged with nitrogen and a vacuum applied to 20-50 mTorr. Thereafter, inert gas (argon, helium or mixture of them) is admitted to the reaction chamber for the plasma treatment. One method uses argon (Ar) gas, operating at a power range from 200 to 400 watts, a flow rate of 150-650 standard ml per minute, which is equivalent to about 100-450 mTorr, and an exposure time from 30 seconds to about 5 minutes. The stents can be removed immediately after the plasma treatment or remain in the argon atmosphere for an additional period of time, typically five minutes.
  • [0037]
    In accordance with the invention, the topcoat or surface coating may be applied in any of several ways to further control thrombolytic effects and optionally, control the release profile especially the initial very high release rate associated with the elution of heparin.
  • [0038]
    In one embodiment, an outer layer of fluorosilicone (FSi) is applied to the undercoat as a topcoat. The outer layer can also contain heparin. In another embodiment, polyethylene glycol (PEG) is immobilized on the surface of the coating. In this process, the underlayer is subjected to inert gas plasma treatment and immediately thereafter is treated by ammonia (NH3) plasma to aminate the surface. Amination, as used in this application, means creating mostly imino groups and other nitro containing species on the surface. This is followed by immediate immersion into electrophilically activated polyethylene glycol (PEG) solution with a reductive agent, i.e., sodium cyanoborohydride.
  • [0039]
    To form a topcoat which is substantially free of pores, porosigens or materials capable of eluting from the topcoat during implantation, should not be included in the composition used to form the topcoat. For example, a substantially non-porous topcoat can be produced from a topcoat composition which comprises a substantially pure polymeric material. The material preferably provides biocompatibility to the implanted device during and after release of the biologically active material.
  • [0040]
    To prepare a topcoat which covers less than the entire surface of the undercoat, a number of methods can be used. For instance, by controlling the thickness of the topcoat so that it has an average thickness less than that of the diameter of certain drug particles, the undercoat will be only partly covered by the topcoat since some of drug particles will not be covered by the topcoat.
  • [0041]
    Also, a partial topcoat can be formed by using a topcoat polymer which is incompatible with the undercoat polymer to generate a microphase separation in the topcoat. Furthermore, to make a topcoat which covers less than the entire surface of the undercoat or which only partially covers the undercoat, a poor solvent wash can be applied to the topcoat, to force the topcoat polymer to shrink so that the undercoat is not entirely covered.
  • [0042]
    In other embodiments the topcoat can partially or fully cover the undercoat prior to delivery or implantation of the device. The topcoat materials can be selected so they have certain water permeability. When water penetrates the topcoat and into the drug particles of the undercoat, the water will swell the particles or dissolve the particles. In either situation, it creates osmotic pressure in the surrounding coating material of the undercoat. The pressure then breaks the thinnest part of the topcoat, and leave the void space in the topcoat for the drug to elute out.
  • [0043]
    In another embodiment, the topcoat material has a different Young's modulus (either while it is wet or dry) than that of the undercoat material. More specifically, the Young's modulus can be higher for the topcoat material. During the mounting of the coated devices onto the delivery device or during deployment of the coated device, the coating undergoes compression or stretching. Topcoat materials with higher Young's modulus tend to crack and form void spaces for the drug to elute from undercoat.
  • [0044]
    Another way to form a topcoat is to cover the undercoat with a bioabsorbable material. In this embodiment, the topcoat can cover either the entire undercoat or only part of the undercoat before or after implantation. Upon contact with body fluids, the bioabsorbable material of the topcoat will degrade. The rate of degradation depends upon the bioabsorbable material used. When the topcoat is partially absorbed, the undercoat is exposed to the body fluid and the drug is released, however the burst effect will be reduced.
  • [0045]
    The coated and cured stents having the modified outer layer or surface optionally are subjected to a final gamma radiation sterilization nominally at 2.5-3.5 Mrad. Argon (Ar) plasma treated stents enjoy full resiliency after radiation whether exposed in a constrained or non-constrained status, while constrained stents subjected to gamma sterilization without Ar plasma pretreatment lose resiliency and do not recover at a sufficient or appropriate rate where the undercoat is silicone.
  • [0046]
    The elastomeric materials that form the stent coating underlayers should possess certain properties. Preferably the layers should be of suitable hydrophobic biostable elastomeric materials which do not degrade. Surface layer or topcoat materials should minimize tissue rejection and tissue inflammation and permit encapsulation by tissue adjacent the stent implantation site. Exposed material is designed to reduce clotting tendencies in blood contacted and the surface is preferably modified accordingly. Thus, underlayers of the above materials are preferably provided with a silicone or a fluorosilicone outer coating layer which should not contain imbedded bioactive material, such as heparin in order to avoid the formation of pores in the topcoat. Alternatively, the outer coating may consist essentially of polyethylene glycol (PEG), polysaccharides, phospholipids, or combinations of the foregoing.
  • [0047]
    Polymers generally suitable for the undercoats or underlayers include silicones (e.g., polysiloxanes and substituted polysiloxanes), polyurethanes, thermoplastic elastomers in general, ethylene vinyl acetate copolymers, polyolefin elastomers, polyamide elastomers, and EPDM rubbers. The above-referenced materials are considered hydrophobic with respect to the contemplated environment of the invention. Surface layer or topcoat materials can include the same polymer as that of the undercoat. Examples of suitable polymers include without limitation fluorosilicones and polyethylene glycol (PEG), polysaccharides, phospholipids, and combinations of the foregoing.
  • [0048]
    While heparin is preferred as the incorporated active material, agents possibly suitable for incorporation include antithrobotics, anticoagulants, antibiotics antiplatelet agents, thrombolytics, antiproliferatives, steroidal and nonsteroidal antiinflammatories, agents that inhibit hyperplasia and in particular restenosis, smooth muscle cell inhibitors, growth factors, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters and drugs that may enhance the formation of healthy neointimal tissue, including endothelial cell regeneration. The positive action may come from inhibiting particular cells (e.g., smooth muscle cells) or tissue formation (e.g., fibromuscular tissue) while encouraging different cell migration (e.g., endothelium) and tissue formation (neointimal tissue).
  • [0049]
    Suitable materials for fabricating the braided stent include stainless steel, tantalum, titanium alloys including nitinol (a nickel titanium, thermomemoried alloy material), and certain cobalt alloys including cobalt-chromium-nickel alloys such as Elgiloy® and Phynox®. Further details concerning the fabrication and details of other aspects of the stents themselves, may be gleaned from the above referenced U.S. Pat. Nos. 4,655,771 and 4,954,126 to Wallsten and U.S. Pat. No. 5,061,275 to Wallsten et al., which are incorporated by reference herein.
  • [0050]
    Various combinations of polymer coating materials can be coordinated with biologically active species of interest to produce desired effects when coated on stents to be implanted in accordance with the invention. Loadings of therapeutic materials may vary. The mechanism of incorporation of the biologically active species into the surface coating, and egress mechanism depend both on the nature of the surface coating polymer and the material to be incorporated. The mechanism of release also depends on the mode of incorporation. The material may elute via interparticle paths or be administered via transport or diffusion through the encapsulating material itself.
  • [0051]
    For the purposes of this specification, “elution” is defined as any process of release that involves extraction or release by direct contact of the material with bodily fluids through the interparticle paths connected with the exterior of the coating. “Transport” or “diffusion” are defined to include a mechanism of release in which the material released traverses through another material.
  • [0052]
    The desired release rate profile can be tailored by varying the coating thickness, the radial distribution (layer to layer) of bioactive materials, the mixing method, the amount of bioactive material, the combination of different matrix polymer materials at different layers, and the crosslink density of the polymeric material. The crosslink density is related to the amount of crosslinking which takes place and also the relative tightness of the matrix created by the particular crosslinking agent used. This, during the curing process, determines the amount of crosslinking and so the crosslink density of the polymer material. For bioactive materials released from the crosslinked matrix, such as heparin, a denser crosslink structure will result in a longer release time and reduced burst effect.
  • [0053]
    It will also be appreciated that an unmedicated silicone thin top layer provides some advantage and additional control over drug elution.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0054]
    In the drawings, wherein like numerals designate like parts throughout the same:
  • [0055]
    FIG. 1 is a schematic flow diagram illustrating the steps of the process of the invention;
  • [0056]
    FIG. 2 represents a release profile for a multi-layer system showing the percentage of heparin released over a two-week period;
  • [0057]
    FIG. 3 represents a release profile for a multi-layer system showing the relative release rate of heparin over a two-week period;
  • [0058]
    FIG. 4 illustrates a profile of release kinetics for different drug loadings at similar coating thicknesses illustrating the release of heparin over a two-week period without associated means to provide a long term non-thrombogenic surface thereafter;
  • [0059]
    FIG. 5 illustrates drug elution kinetics at a given loading of heparin over a two-week period at different coating thicknesses without associated means to provide a long term non-thrombogenic surface thereafter;
  • [0060]
    FIG. 6 illustrates the release kinetics for a given undercoat and topcoat material varied according to thickness in which the percentage heparin in the undercoat and topcoats are kept constant;
  • [0061]
    FIG. 7 is a plot of heparin release kinetics in phosphate buffer system at pH 7.4 with and without fluorosilicone (FSi) topcoat; and
  • [0062]
    FIG. 8 is another plot of heparin release kinetics in phosphate buffer system in which a topcoat containing fluorosilicone (FSi) only is compared with an FSi topcoat containing 16.7% imbedded heparin.
  • [0063]
    FIG. 9 illustrates a surface of an implantable prosthesis covered with an undercoat, containing a biologically active material, which is partly covered by a topcoat.
  • DETAILED DESCRIPTION
  • [0064]
    According to the present invention, the stent coatings incorporating biologically active materials for timed delivery in situ in a body lumen of interest are preferably sprayed in many thin layers from prepared coating solutions or suspensions. The steps of the process are illustrated generally in FIG. 1. The coating solutions or suspensions are prepared at 10 as will be described later. The desired amount of crosslinking agent (if any) is added to the suspension/solution as at 12 and material is then agitated or stirred to produce a homogenous coating composition at 14 which is thereafter transferred to an application container or device which may be a container for spray painting at 16. Typical exemplary preparations of coating solutions that were used for heparin and dexamethasone appear next.
  • [0000]
    General Preparation of Heparin Undercoating Composition
  • [0065]
    Silicone was obtained as a polymer precursor in solvent (xylene) mixture. For example, a 35% solid silicone weight content in xylene was procured from Applied Silicone, Part #40,000. First, the silicone-xylene mixture was weighed. The solid silicone content was determined according to the vendor's analysis. Precalculated amounts of finely divided heparin (2-6 microns) were added into the silicone, then tetrahydrofuran (THF) HPCL grade (Aldrich or EM) was added. For a 37.5% heparin coating, having 35% solids, Wsilicone=5 g and Whep=5×0.35×0.375/(0.625)=1.05 g were used. The amount of THF needed (44 ml) in the coating solution was calculated by using the equation Wsilicone solid/VTHF=0.04 for a 37.5% heparin coating solution. Finally, the manufacturer crosslinker solution was added by using Pasteur P-pipet. The amount of crosslinker added was formed to effect the release rate profile. Typically, five drops of crosslinker solution were added for each five grams of silicone-xylene mixture. The solution was stirred by using the stirring rod until the suspension was homogenous and milk-like. The coating solution was then transferred into a paint jar in condition for application by air brush.
  • [0000]
    General Preparation of Dexamethasone Undercoating Composition
  • [0066]
    Silicone (35% solution as above) was weighed into a beaker on a Metler balance. The weight of dexamethasone free alcohol or acetate form was calculated by silicone weight multiplied by 0.35 and the desired percentage of dexamethasone (1 to 40%) and the required amount was then weighed. Example: Wsilicone=5 g; for a 10% dexamethasone coating, Wdex=5×0.35×0.1/0.9=0.194 g and THF needed in the coating solution and Wsilicone solid/VTHF=0.06 for a 10% dexamethasone coating solution. Example: Wsilicone=5 g; VTHF=5×0.35/0.06≈29 ml. The dexamethasone was weighed in a beaker on an analytical balance and half the total amount of THF was added. The solution was stirred well to ensure full dissolution of the dexamethasone. The stirred DEX-THF solution was then transferred to the silicone container. The beaker was washed with the remaining THF and this was transferred to the silicone container. The crosslinker was added by using a Pasteur pipet. Typically, five drops of crosslinker were used for five grams of silicone.
  • [0067]
    The application of the coating material to the stent was quite similar for all of the materials and the same for the heparin and dexamethasone suspensions prepared as in the above Examples. The suspension to be applied was transferred to an application device, at 16 in FIG. 1. Typically a paint jar attached to an air brush, such as a Badger Model 150, supplied with a source of pressurized air through a regulator (Norgren, 0-160 psi) was used. Once the brush hose was attached to the source of compressed air downstream of the regulator, the air was applied. The pressure was adjusted to approximately 15-25 psi and the nozzle condition checked by depressing the trigger.
  • [0068]
    To secure the stent for spraying and rotating fixtures were utilized successfully in the laboratory. Both ends of the relaxed stent were fastened to the fixture by two resilient retainers, commonly alligator clips, with the distance between the clips adjusted so that the stent remained in a relaxed, unstretched condition. The rotor was then energized and the spin speed adjusted to the desired coating speed, nominally about 40 rpm.
  • [0069]
    With the stent rotating in a substantially horizontal plane, the spray nozzle was adjusted so that the distance from the nozzle to the stent was about 2-4 inches and the composition was sprayed substantially horizontally with the brush being-directed along the stent from the distal end of the stent to the proximal end and then from the proximal end to the distal end in a sweeping motion at a speed such that one spray cycle occurred in about three stent rotations. Typically a pause of less than one minute, normally about one-half minute, elapsed between layers. Of course, the number of coating layers did and will vary with the particular application. For example, typical tie-layers as at 18 in FIG. 1, for a coating level of 3-4 mg of heparin per cm2 of projected area, 20 cycles of coating application are required and about 30 ml of solution will be consumed for a 3.5 mm diameter by 14.5 cm long stent.
  • [0070]
    The rotation speed of the motor, of course, can be adjusted as can the viscosity of the composition and the flow rate of the spray nozzle as desired to modify the layered structure. Generally, with the above mixes, the best results have been obtained at rotational speeds in the range of 30-50 rpm and with a spray nozzle flow rate in the range of 4-10 ml of coating composition per minute, depending on the stent size. It is contemplated that a more sophisticated, computer-controlled coating apparatus will successfully automate the process demonstrated as feasible in the laboratory.
  • [0071]
    Several applied layers make up what is called the undercoat as at 18. In one process, additional upper undercoat layers, which may be of the same or different composition with respect to bioactive material, the matrix. polymeric materials and crosslinking agent, for example, may be applied as the top layer as at 20. The application of the top layer follows the same coating procedure as the undercoat with the number and thickness of layers being optional. of course, the thickness of any layer can be adjusted by adjusting the speed of rotation of the stent and the spraying conditions. Generally, the total coating thickness is controlled by the number of spraying cycles or thin coats which make up the total coat.
  • [0072]
    As shown at 22 in FIG. 1, the coated stent is thereafter subjected to a curing step in which the prepolymer and crosslinking agents cooperate to produce a cured polymer matrix containing the biologically active species. The curing process involves evaporation of the solvent xylene, THF, etc. and the curing and crosslinking of the polymer. Certain silicone materials can be cured at relatively low temperatures, (i.e., RT-50° C.) in what is known as a room temperature vulcanization (RTV) process. More typically, however, the curing process involves higher temperature curing materials and the coated stents are put into an oven at approximately 90° C. or higher for approximately 16 hours. The temperature may be raised to as high as 150° C. for dexamethasone containing coated stents. Of course, the time and temperature may vary with particular silicones, crosslinkers and biologically active species.
  • [0073]
    Stents coated and cured in the manner described need to be sterilized prior to packaging for future implantation. For sterilization, gamma radiation is a preferred method particularly for heparin containing coatings; however, it has been found that stents coated and cured according to the process of the invention subjected to gamma sterilization may be too slow to recover their original posture when delivered to a vascular or other lumen site using a catheter unless a pretreatment step as at 24 is first applied to the coated, cured stent.
  • [0074]
    The pretreatment step involves an argon plasma treatment of the coated, cured stents in the unconstrained configuration. In accordance with this procedure, the stents are placed in a chamber of a plasma surface treatment system such as a Plasma Science 350 (Himont/Plasma Science, Foster City, Calif.). The system is equipped with a reactor chamber and RF solid-state generator operating at 13.56 mHz and from 0-500 watts power output and being equipped with a microprocessor controlled system and a complete vacuum pump package. The reaction chamber contains an unimpeded work volume of 16.75 inches (42.55 cm) by 13.5 inches (34.3 cm) by 17.5 inches (44.45 cm) in depth.
  • [0075]
    In the plasma process, unconstrained coated stents are placed in a reactor chamber and the system is purged with nitrogen and a vacuum applied to 20-50 mTorr. Thereafter, inert gas (argon, helium or mixture of them) is admitted to the reaction chamber for the plasma treatment. A highly preferred method of operation consists of using argon gas, operating at a power range from 200 to 400 watts, a flow rate of 150-650 standard ml per minute, which is equivalent to 100-450 mTorr, and an exposure time from 30 seconds to about 5 minutes. The stents can be removed immediately after the plasma treatment or remain in the argon atmosphere for an additional period of time, typically five minutes.
  • [0076]
    After this, as shown at 26, the stents may be exposed to gamma sterilization at 2.5-3.5 Mrad. The radiation may be carried out with the stent in either the radially unconstrained status or in the radially constrained status.
  • [0077]
    Preferably, however, the surface is modified prior to plasma treatment or just prior to sterilization by one of several additional processing methods of which some are described in relation to the following examples.
  • EXAMPLE 1 Fluorosilicone Surface Treatment of Eluting Heparin Coating
  • [0078]
    The undercoat of a stent was coated as multiple applied layers as described above thereafter and cured as described at 22. The heparin content of the undercoat was 37.5% and the coating thickness was about 30-40μ. Fluorosilicone (FSi) spray solution was prepared at 30 from a fluorosilicone suspension (Applied Silicone #40032) by weighing an amount of fluorosilicone suspension and adding tetrahydrofuran (THF) according to the relation equation of VTHF=1.2× the weight of fluorosilicone suspension. The solution was stirred very well and spray-coated on the stent at 32 using the technique of the application of the undercoat process at 18 and the coated stents were cured at 90° C. for 16 hours. The coated stents are argon plasma treated prior to gamma sterilization according to the procedures described above in accordance with steps 22-26.
  • [0079]
    FIG. 7 is a plot of heparin release kinetics in phosphate buffer system with fluorosilicone topcoat and without any topcoat. The thickness of the topcoat is about 10-15 A. While it does not appear on the graph of FIG. 7 it should be noted that the release rate for the coating without FSi is initially about 25 times higher than that with FSi, i.e., during the first 2 hours. This is, of course, clearly off the scale of the graph. It is noteworthy, however, that the coating with the FSi top layer or diffusion barrier does show a depressed initial release rate combined with an enhanced elution rate after the first day and through the first week up until about the tenth day. In addition, the fluorosilicone (FSi) topcoat, by virtue of the high electronegativity of fluorination maintains non-thrombogenic surface qualities during and after the elusion of the biologically active heparin species. In addition, because of the negative charges off the heparin itself, the electro-negativity of the fluorosilicone topcoat may be, at least in part, responsible for the modified heparin release kinetic profile.
  • [0080]
    FIG. 8 compares a plot of fluorosilicone (FSi) top coating containing 16.7% imbedded heparin with one containing fluorosilicone (FSi) only. An undercoating is identical to that utilized in FIG. 7 containing about 37.5% heparin to a thickness of about 30-40 microns. These elution kinetics are quite comparable with the heparin-free FSi top layer greatly reducing the initial burst of heparin release and otherwise the heparin in the FSi top layer imparts a slightly greater release over the period of the test.
  • EXAMPLE 2 Immobilization of Polyethylene Glycol (PEG) on Drug Eluting Undercoat
  • [0081]
    An undercoat was coated on a stent and cured at 22 as in Example 1. The stent was then treated by argon gas plasma as at 24 and ammonium gas plasma at 40. The equipment and the process of argon gas plasma treatment was as has been described above. The ammonium plasma treatment was implemented immediately after the argon gas plasma treatment, to aminate the surface of the coating. The ammonium flow rate was in the range of 100-700 cubic centimeter per minute (ccM) in preferably in the range of 500-600 ccM. The power output of radio frequency plasma was in the range of 50-500 watts, preferably in ˜200 watts. The process time was in the range of 30 sec-10 min, preferably ˜5 min.
  • [0082]
    Immediately after amination, the stents were immersed into electrophilically activated polyethylene glycol (PEG) solution it 42. PEG is known to be an inhibitor of protein absorption. Examples of electrophilically activated PEG are PEG nitrophenyl carbonates, PEG trichlorophenyl carbonates, PEG tresylate, PEG glycidyl ether, PEG isocyanate, etc., optionally with one end terminated with methoxyl group. Molecular weight of PEG ranged from about 1000-6000, and is preferable about 3000. It has been observed that simple ammonium amination will not generate large quantities of primary and secondary amines on the elastomeric polymer surface (for example silicone). Instead, imine (>C═N—H), and other more oxidative nitro containing groups will dominate the surface. It is generally necessary to add reductive agent, such as NaBH3CN into the reaction media so that the functional group on PEG can react with imine and possibly other nitro-containing species on the surface, and therefore immobilize PEG onto the surface. The typical concentration of NaBH3CN is about 2 mg/ml. Since PEG and its derivatives dissolve in water and many polar and aromatic solvents, the solvent used in the coating must be a solvent for PEG but not for the drug in the undercoat to prevent the possible loss of the drug through leaching. In the case of eluting-heparin coating, a mixed solvent of formamide and methyl ethyl ketone (MEK) or a mixed solvent of formamide and acetone are preferred solvents, (preferably at ratios of 30 formamide: 70 MEK or acetone by volume), since they will not dissolve heparin. The concentration of PEG, the reaction time, the reaction temperature and the pH value depend on the kind of PEG employed. In the case of eluting heparin coating, 5% PEG tresylate in (30-70) Formamide/MEK was used successfully. The reaction time was 3 hours at room temperature. PEG was then covalently bound to the surface. Gamma radiation was then used for sterilization of this embodiment as previously described.
  • [0083]
    With respect to the anticoagulant material heparin, the percentage in the undercoat is nominally from about 30-50% and that of the topcoat from about 0-30% active material. The coating thickness ratio of the topcoat to the undercoat varies from about 1:10 to 1:2 and is preferably in the range of from about 1:6 to 1:3.
  • [0084]
    To produce a topcoat which is substantially free of pores, materials such as porosigens, which can be removed or leached out of the topcoat should not be included in the composition used to form the topcoat. One way of preparing a substantially non-porous topcoat is to apply a topcoat composition which comprises substantially pure polymeric materials. These materials preferably impart biocompatibility to the implanted device during and after the release of the biologically active material.
  • [0085]
    A topcoat which only partially covers the undercoat can be formed in a number of ways. Such methods include controlling the thickness of the topcoat so that it is less than the diameter of certain drug particles in the undercoat. For example, when a drug used in the undercoat has an average particle size of 5 μm, it is possible that 15% of the particles will be greater than or equal to 8 μm. At the molecular level, the surface unevenness is at least more than 5 microns. By application of a topcoat of about 5 micron or less. The uneven surface will become smooth to a certain degree. But uncovered areas will still exist, which allows water to penetrate into the undercoat, swelling the drug particle, or dissolving the drug. Due to the osmotic pressure, the drug will elute out through the uncovered areas. If the osmotic pressure is too high, cracks or voids may form in the topcoat which allows drugs to elute from the undercoat to the body.
  • [0086]
    As illustrated in FIG. 9, in a coating 102 which covers a surface of a prosthesis 101, a thin topcoat 104 of the coating 102 only partially covers the undercoat 103 of the coating 102. By having the topcoat 104 cover less than the entire surface of the undercoat 103, parts of the undercoat 103, including a number of drug particles 105, are exposed to body fluids at the implantation site so that the drug 105 can be released. By using a topcoat 104 having a thickness which is about the average particle size of the drug 105, certain larger sized drug particles 106 will not be covered by the topcoat 104.
  • [0087]
    Other methods to form a partially covered topcoat include using a polymer which is incompatible to the undercoat elastomer as the biocompatible material of the topcoat. Because of the incompatibility between the materials, a microphase separation will form in the topcoat which will leave the undercoat partially uncovered. Persons skilled in the art are aware of suitable combinations of such incompatible materials.
  • [0088]
    Another method involves applying a poor solvent wash to the topcoat to force the biocompatible polymer to shrink and create uneven surfaces voids in the topcoat which forms a topcoat which partially covers the undercoat.
  • [0089]
    In yet another method of making a topcoat which partly or fully covers the undercoat, topcoat and undercoat materials having different Young's moduli (either before or after they have cured) are used. For instance, a topcoat material having a higher Young's modulus compared to that of the undercoat material can be employed. When the coated device is mounted on the delivery device or during deployment of the coated device, the topcoat undergoes compression or stretching or other types of mechanical challenges. Since the topcoat material has a higher Young's modulus, it will tend to crack and form voids in the topcoat to allow the drug of the undercoat to elute therefrom.
  • [0090]
    Another method for forming the topcoat involves using a bioabsorbable material in the topcoat, which can cover the entire undercoat or only a part of the undercoat. When the coated device comes into contact with body fluid, the topcoat begins to degrade either at the surface or throughout the bulk of the topcoat. The rate of degradation depends upon the type of bioabsorbable material used. Once the topcoat has been partially absorbed, the undercoat is exposed to body tissue and the drug in the undercoat is released, but the burst release or effect is reduced.
  • [0091]
    Suppressing the burst effect also enables a reduction in the drug loading or in other words, allows a reduction in the coating thickness, since the physician will give a bolus injection of antiplatelet/anticoagulation drugs to the patient during the stenting process. As a result, the drug imbedded in the stent can be fully used without waste. Tailoring the first day release, but maximizing second day and third day release at the thinnest possible coating configuration will reduce the acute or subacute thrombosis particularly if drugs such as heparin are incorporated.
  • [0092]
    FIG. 4 depicts the general effect of drug loading for coatings of similar thickness. The initial elution rate increases with the drug loading as shown in FIG. 5. The release rate also increases with the thickness of the coating at the same loading but tends to be inversely proportional to the thickness of the topcoat as shown by the same drug loading and similar undercoat thickness in FIG. 6.
  • [0093]
    What is apparent from the data gathered to date, however, is that the process of the present invention enables the drug elution kinetics to be controlled in a manner desired to meet the needs of the particular stent application. In a similar manner, stent coatings can be prepared using a combination of two or more drugs and the drug release sequence and rate controlled. For example, antiproliferation drugs may be combined in the undercoat and antiplatelet drugs in the topcoat. In this manner, the antiplatelet drugs, for example, heparin, will elute first followed by antiproliferation drugs to better enable safe encapsulation of the implanted stent.
  • [0094]
    The heparin concentration measurement were made utilizing a standard curve prepared by complexing azure A dye with dilute solutions of heparin. Sixteen standards were used to compile the standard curve in a well-known manner.
  • [0095]
    For the elution test, the stents were immersed in a phosphate buffer solution at pH 7.4 in an incubator at approximately 37° C. Periodic samplings of the solution were processed to determine the amount of heparin eluted. After each sampling, each stent was placed in heparin-free buffer solution.
  • [0096]
    As stated above, while the allowable loading of the elastomeric material with heparin may vary, in the case of silicone materials, heparin may exceed 60% of the total weight of the layer. However, the loading generally most advantageously used is in the range from about 10% to 45% of the total weight of the layer. In the case of dexamethasone, the loading may be as high as 50% or more of the total weight of the layer but is preferably in the range of about 0.4% to 45%.
  • [0097]
    It will be appreciated that the mechanism of incorporation of the biologically active species into a thin surface coating structure applicable to a metal stent is an important aspect of the present invention. The need for relatively thick-walled polymer elution stents or any membrane overlayers associated with many prior drug elution devices is obviated, as is the need for utilizing biodegradable or reabsorbable vehicles for carrying the biologically active species. The technique clearly enables long-term delivery and minimizes interference with the independent mechanical or therapeutic benefits of the stent itself.
  • [0098]
    Coating materials are designed with a particular coating technique, coating/drug combination and drug infusion mechanism in mind. Consideration of the particular form and mechanism of release of the biologically active species in the coating allow the technique to produce superior results. In this manner, delivery of the biologically active species from the coating structure can be tailored to accommodate a variety of applications.
  • [0099]
    Whereas the above examples depict coatings having two different drug loadings or percentages of biologically active material to be released, this is by no means limiting with respect to the invention and it is contemplated that any number of layers and combinations of loadings can be employed to achieve a desired release profile. For example, gradual grading and change in the loading of the layers can be utilized in which, for example, higher loadings are used in the inner layers. Also layers can be used which have no drug loadings at all. For example, a pulsatile heparin release system may be achieved by a coating in which alternate layers containing heparin are sandwiched between unloaded layers of silicone or other materials for a portion of the coating. In other words, the invention allows untold numbers of combinations which result in a great deal of flexibility with respect to controlling the release of biologically active materials with regard to an implanted stent. Each applied layer is typically from approximately 0.5 microns to 15 microns in thickness. The total number of sprayed layers, of course, can vary widely, from less than 10 to more than 50 layers; commonly, 20 to 40 layers are included. The total thickness of the coating can also vary widely, but can generally be, from about 10 to 200 microns.
  • [0100]
    Whereas the polymer of the coating may be any compatible biostable elastomeric material capable of being adhered to the stent material as a thin layer, hydrophobic materials are preferred because it has been found that the release of the biologically active species can generally be more predictably controlled with such materials. Preferred materials include silicone rubber elastomers and biostable polyurethanes specifically.
  • [0101]
    This invention has been described herein in considerable detail in order to comply with the Patent Statutes and to provide those skilled in the art with the information needed to apply the novel principles and to construct and use embodiments of the example as required. However, it is to be understood that the invention can be carried out by specifically different devices and that various modifications can be accomplished without departing from the scope of the invention itself.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US478500 *Dec 9, 1891Jul 5, 1892 clark
US3279996 *Aug 28, 1962Oct 18, 1966Folkman Moses JudahPolysiloxane carrier for controlled release of drugs and other agents
US3526005 *Jun 29, 1967Sep 1, 1970Gulf General Atomic IncMethod of preparing an intravascular defect by implanting a pyrolytic carbon coated prosthesis
US3738365 *Nov 1, 1971Jun 12, 1973Schulte RSpring reinforced extensible catheter
US3879516 *Dec 7, 1972Apr 22, 1975TechnibioticsMethod of constructing a catheter
US3932627 *Feb 4, 1974Jan 13, 1976Rescue Products, Inc.Siver-heparin-allantoin complex
US3952334 *Nov 29, 1974Apr 27, 1976General Atomic CompanyBiocompatible carbon prosthetic devices
US4219520 *Aug 30, 1978Aug 26, 1980Medical Evaluation Devices And Instruments Corp.Method of making thrombo-resistant non-thrombogenic objects formed from a uniform mixture of a particulate resin and colloidal graphite
US4292965 *Dec 29, 1978Oct 6, 1981The Population Council, Inc.Intravaginal ring
US4613665 *Feb 8, 1983Sep 23, 1986Olle LarmProcess for covalent coupling for the production of conjugates, and polysaccharide containing products thereby obtained
US4655771 *Apr 11, 1983Apr 7, 1987Shepherd Patents S.A.Prosthesis comprising an expansible or contractile tubular body
US4656083 *Mar 11, 1985Apr 7, 1987Washington Research FoundationPlasma gas discharge treatment for improving the biocompatibility of biomaterials
US4678466 *Dec 27, 1985Jul 7, 1987Rosenwald Peter LInternal medication delivery method and vehicle
US4687482 *Apr 27, 1984Aug 18, 1987Scripps Clinic And Research FoundationVascular prosthesis
US4689046 *Mar 11, 1985Aug 25, 1987Carbomedics, Inc.Heart valve prosthesis
US4739762 *Nov 3, 1986Apr 26, 1988Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4753652 *Dec 10, 1986Jun 28, 1988Children's Medical Center CorporationBiomaterial implants which resist calcification
US4768507 *Aug 31, 1987Sep 6, 1988Medinnovations, Inc.Intravascular stent and percutaneous insertion catheter system for the dilation of an arterial stenosis and the prevention of arterial restenosis
US4776337 *Jun 26, 1986Oct 11, 1988Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4872867 *Feb 28, 1989Oct 10, 1989Ube Industries, Ltd.Compositions having antithrombogenic properties and blood contact medical devices using the same
US4894231 *Jul 28, 1987Jan 16, 1990Biomeasure, Inc.Therapeutic agent delivery system
US4916193 *Aug 1, 1988Apr 10, 1990Allied-Signal Inc.Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US4922905 *May 28, 1987May 8, 1990Strecker Ernst PDilatation catheter
US4954126 *Mar 28, 1989Sep 4, 1990Shepherd Patents S.A.Prosthesis comprising an expansible or contractile tubular body
US4990158 *May 10, 1989Feb 5, 1991United States Surgical CorporationSynthetic semiabsorbable tubular prosthesis
US4994071 *May 22, 1989Feb 19, 1991Cordis CorporationBifurcating stent apparatus and method
US5019096 *Oct 14, 1988May 28, 1991Trustees Of Columbia University In The City Of New YorkInfection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5034265 *Aug 21, 1989Jul 23, 1991Washington Research FoundationPlasma gas discharge treatment for improving the compatibility of biomaterials
US5053048 *Nov 8, 1990Oct 1, 1991Cordis CorporationThromboresistant coating
US5059166 *Dec 11, 1989Oct 22, 1991Medical Innovative Technologies R & D Limited PartnershipIntra-arterial stent with the capability to inhibit intimal hyperplasia
US5061275 *Dec 29, 1989Oct 29, 1991Medinvent S.A.Self-expanding prosthesis
US5092877 *Jul 5, 1990Mar 3, 1992Corvita CorporationRadially expandable endoprosthesis
US5102417 *Mar 28, 1988Apr 7, 1992Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US5180366 *Oct 10, 1990Jan 19, 1993Woods W TApparatus and method for angioplasty and for preventing re-stenosis
US5180376 *May 1, 1990Jan 19, 1993Cathco, Inc.Non-buckling thin-walled sheath for the percutaneous insertion of intraluminal catheters
US5182317 *Jun 17, 1991Jan 26, 1993Cardiopulmonics, Inc.Multifunctional thrombo-resistant coatings and methods of manufacture
US5185408 *Nov 18, 1991Feb 9, 1993Allied-Signal Inc.Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5192308 *Apr 19, 1991Mar 9, 1993E. I. Du Pont De Nemours And CompanyVascular prosthesis with an elastomer coating
US5199951 *Sep 13, 1991Apr 6, 1993Wayne State UniversityMethod of drug application in a transporting medium to an arterial wall injured during angioplasty
US5222971 *Oct 9, 1990Jun 29, 1993Scimed Life Systems, Inc.Temporary stent and methods for use and manufacture
US5226913 *Mar 2, 1992Jul 13, 1993Corvita CorporationMethod of making a radially expandable prosthesis
US5282823 *Mar 19, 1992Feb 1, 1994Medtronic, Inc.Intravascular radially expandable stent
US5288711 *Apr 28, 1992Feb 22, 1994American Home Products CorporationMethod of treating hyperproliferative vascular disease
US5292802 *Dec 2, 1992Mar 8, 1994Collagen CorporationCollagen-polymer tubes for use in vascular surgery
US5304121 *Nov 22, 1991Apr 19, 1994Boston Scientific CorporationDrug delivery system making use of a hydrogel polymer coating
US5308889 *Dec 2, 1992May 3, 1994Collagen CorporationDehydrated collagen-polymer strings
US5318779 *Mar 15, 1990Jun 7, 1994Olympus Optical Co., Ltd.Drug-impregnated ceramic
US5338770 *Apr 12, 1990Aug 16, 1994Cardiopulmonics, Inc.Gas permeable thrombo-resistant coatings and methods of manufacture
US5342348 *Dec 4, 1992Aug 30, 1994Kaplan Aaron VMethod and device for treating and enlarging body lumens
US5344411 *Nov 3, 1993Sep 6, 1994Leonard BloomMethod and device for inhibiting HIV, hepatitis B and other viruses and germs when using a catheter in a medical environment
US5356433 *Nov 3, 1993Oct 18, 1994Cordis CorporationBiocompatible metal surfaces
US5378475 *Feb 21, 1991Jan 3, 1995University Of Kentucky Research FoundationSustained release drug delivery devices
US5380299 *Aug 30, 1993Jan 10, 1995Med Institute, Inc.Thrombolytic treated intravascular medical device
US5383928 *Aug 19, 1993Jan 24, 1995Emory UniversityStent sheath for local drug delivery
US5391378 *Feb 22, 1993Feb 21, 1995Elizabeth-Hata International, Inc.Two-part medicinal tablet and method of manufacture
US5399352 *Apr 14, 1993Mar 21, 1995Emory UniversityDevice for local drug delivery and methods for using the same
US5415619 *Nov 5, 1993May 16, 1995Korea Research Institute Of Chemical Tech.Method of manufacturing a vascular graft impregnated with polysaccharide derivatives
US5419760 *Oct 11, 1994May 30, 1995Pdt Systems, Inc.Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429618 *Mar 14, 1994Jul 4, 1995Medtronic, Inc.Thromboresistant articles
US5443500 *Apr 8, 1994Aug 22, 1995Advanced Cardiovascular Systems, Inc.Intravascular stent
US5447724 *Nov 15, 1993Sep 5, 1995Harbor Medical Devices, Inc.Medical device polymer
US5449382 *Mar 2, 1994Sep 12, 1995Dayton; Michael P.Minimally invasive bioactivated endoprosthesis for vessel repair
US5486357 *Oct 27, 1993Jan 23, 1996Cordis CorporationRadiofrequency plasma biocompatibility treatment of inside surfaces
US5492895 *Feb 14, 1994Feb 20, 1996Corvas International, Inc.Inhibitors of thrombosis
US5496557 *Jan 30, 1991Mar 5, 1996Akzo N.V.Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances
US5500013 *Jan 13, 1995Mar 19, 1996Scimed Life Systems, Inc.Biodegradable drug delivery vascular stent
US5510077 *Sep 15, 1994Apr 23, 1996Dinh; Thomas Q.Method of making an intraluminal stent
US5512055 *Sep 30, 1994Apr 30, 1996Leonard BloomAnti-infective and anti-inflammatory releasing systems for medical devices
US5523092 *Jan 28, 1994Jun 4, 1996Emory UniversityDevice for local drug delivery and methods for using the same
US5545208 *Dec 21, 1993Aug 13, 1996Medtronic, Inc.Intralumenal drug eluting prosthesis
US5551954 *Oct 12, 1994Sep 3, 1996Scimed Life Systems, Inc.Biodegradable drug delivery vascular stent
US5569463 *Jun 7, 1995Oct 29, 1996Harbor Medical Devices, Inc.Medical device polymer
US5591224 *Sep 15, 1994Jan 7, 1997Medtronic, Inc.Bioelastomeric stent
US5591227 *Apr 27, 1995Jan 7, 1997Medtronic, Inc.Drug eluting stent
US5599352 *Sep 15, 1994Feb 4, 1997Medtronic, Inc.Method of making a drug eluting stent
US5605696 *Mar 30, 1995Feb 25, 1997Advanced Cardiovascular Systems, Inc.Drug loaded polymeric material and method of manufacture
US5607463 *Mar 30, 1993Mar 4, 1997Medtronic, Inc.Intravascular medical device
US5609629 *Jun 7, 1995Mar 11, 1997Med Institute, Inc.Coated implantable medical device
US5624411 *Jun 7, 1995Apr 29, 1997Medtronic, Inc.Intravascular stent and method
US5629077 *Jun 27, 1994May 13, 1997Advanced Cardiovascular Systems, Inc.Biodegradable mesh and film stent
US5632840 *Jun 6, 1995May 27, 1997Advanced Cardiovascular System, Inc.Method of making metal reinforced polymer stent
US5637113 *Dec 13, 1994Jun 10, 1997Advanced Cardiovascular Systems, Inc.Polymer film for wrapping a stent structure
US5643580 *Oct 17, 1994Jul 1, 1997Surface Genesis, Inc.Biocompatible coating, medical device using the same and methods
US5662712 *Jun 7, 1995Sep 2, 1997Focal, Inc.Apparatus for intraluminal photothermoforming
US5716981 *Jun 7, 1995Feb 10, 1998Angiogenesis Technologies, Inc.Anti-angiogenic compositions and methods of use
US5722984 *Jan 16, 1996Mar 3, 1998Iso Stent, Inc.Antithrombogenic radioactive coating for an intravascular stent
US5735897 *Jan 2, 1997Apr 7, 1998Scimed Life Systems, Inc.Intravascular stent pump
US5749915 *Jun 7, 1995May 12, 1998Focal, Inc.Polymeric endoluminal paving process
US5776184 *Oct 9, 1996Jul 7, 1998Medtronic, Inc.Intravasoular stent and method
US5779732 *Mar 31, 1997Jul 14, 1998Medtronic, Inc.Method and apparatus for implanting a film with an exandable stent
US5877224 *Jul 28, 1995Mar 2, 1999Rutgers, The State University Of New JerseyPolymeric drug formulations
US5879034 *Oct 17, 1997Mar 9, 1999Johns; Ernest W.Automatic locking device
US5900246 *Jun 5, 1995May 4, 1999Cedars-Sinai Medical CenterDrug incorporating and releasing polymeric coating for bioprosthesis
US6042875 *Mar 2, 1999Mar 28, 2000Schneider (Usa) Inc.Drug-releasing coatings for medical devices
US6096070 *May 16, 1996Aug 1, 2000Med Institute Inc.Coated implantable medical device
US6099562 *Dec 22, 1997Aug 8, 2000Schneider (Usa) Inc.Drug coating with topcoat
US6110483 *Jun 23, 1997Aug 29, 2000Sts Biopolymers, Inc.Adherent, flexible hydrogel and medicated coatings
US6120536 *Jun 13, 1996Sep 19, 2000Schneider (Usa) Inc.Medical devices with long term non-thrombogenic coatings
US6198016 *Jun 10, 1999Mar 6, 20013M Innovative Properties CompanyWet skin adhesive article
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7815675Oct 19, 2010Boston Scientific Scimed, Inc.Stent with protruding branch portion for bifurcated vessels
US7833266Nov 28, 2007Nov 16, 2010Boston Scientific Scimed, Inc.Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment
US7842082Aug 30, 2007Nov 30, 2010Boston Scientific Scimed, Inc.Bifurcated stent
US7951191Sep 5, 2007May 31, 2011Boston Scientific Scimed, Inc.Bifurcated stent with entire circumferential petal
US7951192Aug 25, 2009May 31, 2011Boston Scientific Scimed, Inc.Stent with protruding branch portion for bifurcated vessels
US7955382Sep 14, 2007Jun 7, 2011Boston Scientific Scimed, Inc.Endoprosthesis with adjustable surface features
US7959669Sep 12, 2007Jun 14, 2011Boston Scientific Scimed, Inc.Bifurcated stent with open ended side branch support
US7985252Jul 30, 2008Jul 26, 2011Boston Scientific Scimed, Inc.Bioerodible endoprosthesis
US7998192May 9, 2008Aug 16, 2011Boston Scientific Scimed, Inc.Endoprostheses
US8002821Sep 13, 2007Aug 23, 2011Boston Scientific Scimed, Inc.Bioerodible metallic ENDOPROSTHESES
US8016878Jun 1, 2009Sep 13, 2011Boston Scientific Scimed, Inc.Bifurcation stent pattern
US8048150Apr 12, 2006Nov 1, 2011Boston Scientific Scimed, Inc.Endoprosthesis having a fiber meshwork disposed thereon
US8052743Aug 2, 2007Nov 8, 2011Boston Scientific Scimed, Inc.Endoprosthesis with three-dimensional disintegration control
US8052744Sep 13, 2007Nov 8, 2011Boston Scientific Scimed, Inc.Medical devices and methods of making the same
US8052745Sep 13, 2007Nov 8, 2011Boston Scientific Scimed, Inc.Endoprosthesis
US8057534Sep 14, 2007Nov 15, 2011Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8080055Dec 27, 2007Dec 20, 2011Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8089029Feb 1, 2006Jan 3, 2012Boston Scientific Scimed, Inc.Bioabsorbable metal medical device and method of manufacture
US8128689Sep 14, 2007Mar 6, 2012Boston Scientific Scimed, Inc.Bioerodible endoprosthesis with biostable inorganic layers
US8133553Jun 18, 2007Mar 13, 2012Zimmer, Inc.Process for forming a ceramic layer
US8147539Dec 11, 2007Apr 3, 2012Boston Scientific Scimed, Inc.Stent with a coating for delivering a therapeutic agent
US8236046Jun 10, 2008Aug 7, 2012Boston Scientific Scimed, Inc.Bioerodible endoprosthesis
US8236048Apr 27, 2004Aug 7, 2012Cordis CorporationDrug/drug delivery systems for the prevention and treatment of vascular disease
US8267992Mar 2, 2010Sep 18, 2012Boston Scientific Scimed, Inc.Self-buffering medical implants
US8277501Dec 21, 2007Oct 2, 2012Boston Scientific Scimed, Inc.Bi-stable bifurcated stent petal geometry
US8303609Sep 28, 2001Nov 6, 2012Cordis CorporationCoated medical devices
US8303643May 21, 2010Nov 6, 2012Remon Medical Technologies Ltd.Method and device for electrochemical formation of therapeutic species in vivo
US8309521Jun 19, 2007Nov 13, 2012Zimmer, Inc.Spacer with a coating thereon for use with an implant device
US8372399Aug 31, 2006Feb 12, 2013Cardiac Pacemakers, Inc.Bispecific antibodies and agents to enhance stem cell homing
US8382824Oct 3, 2008Feb 26, 2013Boston Scientific Scimed, Inc.Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8425590May 31, 2011Apr 23, 2013Boston Scientific Scimed, Inc.Stent with protruding branch portion for bifurcated vessels
US8449901Mar 7, 2006May 28, 2013Innovational Holdings, LlcImplantable medical device with beneficial agent concentration gradient
US8602290Apr 22, 2011Dec 10, 2013Zimmer, Inc.Method for bonding a tantalum structure to a cobalt-alloy substrate
US8608049Oct 10, 2007Dec 17, 2013Zimmer, Inc.Method for bonding a tantalum structure to a cobalt-alloy substrate
US8636995Aug 31, 2006Jan 28, 2014Cardiac Pacemakers, Inc.Methods and devices to regulate stem cell homing
US8663337Mar 6, 2012Mar 4, 2014Zimmer, Inc.Process for forming a ceramic layer
US8668732Mar 22, 2011Mar 11, 2014Boston Scientific Scimed, Inc.Surface treated bioerodible metal endoprostheses
US8715339Nov 21, 2011May 6, 2014Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8808726Sep 14, 2007Aug 19, 2014Boston Scientific Scimed. Inc.Bioerodible endoprostheses and methods of making the same
US8840660Jan 5, 2006Sep 23, 2014Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8932340May 29, 2008Jan 13, 2015Boston Scientific Scimed, Inc.Bifurcated stent and delivery system
US20030099682 *Jan 31, 2002May 29, 2003Francis MoussyApparatus and method for control of tissue/implant interactions
US20050131532 *Dec 10, 2004Jun 16, 2005Avantec Vascular CorporationApparatus and methods for controlled substance delivery from implanted prostheses
US20080057027 *Aug 31, 2006Mar 6, 2008Cardiac Pacemakers, IncMethods and devices to regulate stem cell homing
US20080057053 *Aug 31, 2006Mar 6, 2008Cardiac Pacemakers, IncBispecific antibodies and agents to enhance stem cell homing
US20080058922 *Aug 31, 2006Mar 6, 2008Cardiac Pacemakers, Inc.Methods and devices employing vap-1 inhibitors
US20100028403 *Jul 29, 2009Feb 4, 2010Boston Scientific Scimed, Inc.Medical devices for therapeutic agent delivery
WO2008017814A1Aug 3, 2007Feb 14, 2008Sinclair Pharmaceuticals LtdPrevention and treatment of microbial infection
WO2010014690A2Jul 29, 2009Feb 4, 2010Boston Scientific Scimed, Inc.Medical devices for therapeutic agent delivery
Classifications
U.S. Classification623/1.15, 623/1.42
International ClassificationA61L27/00, A61K47/34, A61K47/32, A61L27/22, A61L33/10, A61M37/00, A61K9/00, A61F2/90, A61F2/82, A61F2/86, A61L31/16, A61L31/08, A61L33/00, A61L31/14, A61F2/00, A61L31/10
Cooperative ClassificationA61L31/141, A61F2/82, A61L2420/08, A61L27/227, A61L31/10, A61F2250/0067, A61L2300/416, A61L2300/606, A61F2/90, A61L2300/42, A61L2300/602, A61L31/08, A61L2300/406, A61L2300/608, A61L2300/236, A61L33/0011, A61F2210/0014, A61L31/16, A61F2/86
European ClassificationA61L27/22R, A61F2/90, A61L31/08, A61L31/14B, A61L31/10, A61L33/00H2, A61L31/16, A61F2/86, A61F2/82
Legal Events
DateCodeEventDescription
Jun 17, 2010ASAssignment
Owner name: SCHNEIDER (USA) INC.,MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DING, NI;HELMUS, MICHAEL N.;SIGNING DATES FROM 19971209 TO 19971210;REEL/FRAME:024552/0893
Jun 21, 2010ASAssignment
Owner name: BOSTON SCIENTIFIC SCIMED, INC.,MINNESOTA
Free format text: CHANGE OF NAME;ASSIGNOR:SCHNEIDER (USA) INC.;REEL/FRAME:024564/0518
Effective date: 19990427